Rilmakalim is a chemical compound known for its role as a potassium channel opener, primarily affecting the ATP-sensitive potassium channels. It is classified under the category of pharmacological agents and has been studied for its potential therapeutic applications, particularly in cardiovascular and neuroprotective contexts. The compound exhibits properties that can lead to vasodilation and may influence insulin secretion, making it of interest in diabetes research. Rilmakalim's mechanism of action involves hyperpolarization of cell membranes, which can result in various physiological effects. Its chemical structure includes specific functional groups that contribute to its activity and solubility. As with many pharmacological agents, the safety profile, dosage, and potential side effects are critical considerations in its application. Research continues to explore its efficacy and mechanisms, contributing to a better understanding of its potential uses in clinical settings.

Rilmakalim

132014-21-2:  Rilmakalime,  Rilmakalimum, Rilmakalim [INN],  2-Pyrrolidinone, 1-(3,4-dihydro-3-hydroxy-2,2-dimethyl-6-(phenylsulfonyl)-2H-1-benzopyran-4-yl)-, (3S-trans)-,  UNII-47Y56T6LEI,  Rilmakalimum [INN-Latin],  1-[(3S,4R)-3-hydroxy-2,2-dimethyl-6-(phenylsulfonyl)-3,4-dihydro-2H-chromen-4-yl]pyrrolidin-2-one,  (+)-1-((3S,4R)-3-hydroxy-2,2-dimethyl-6-(phenylsulfonyl)-4-chromanyl)-2-pyrrolidinone,  Rilmakalime [INN-French],  Hoe 234

Rilmakalim is a potassium channel opener. Rilmakalim shows antivasoconstrictor effect.

CAS 132014-21-2: Rilmakalim

Rilmakalim

Ref: TM-T26086

Rilmakalim

Ref: 54-BUP00991